Latest news
Pathos AI Licenses Alphamab's TROP2/HER3 Bispecific ADC, JSKN016 - BioPharm InternationalBioPharm International · Tue, 04 Aug 2026 17:01:14 GMTPromatix secures Innovate UK grant to advance cis-bispecific ADC programme - Manufacturing ChemistManufacturing Chemist · Tue, 04 Aug 2026 12:14:55 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMTMerck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination - fiercebiotech.comfiercebiotech.com · Wed, 29 Jul 2026 07:00:00 GMTPromatix Biosciences Awarded Innovate UK Biomedical - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 07:30:00 GMTNew Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs - BenzingaBenzinga · Tue, 28 Jul 2026 07:00:00 GMTPromatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC - Yahoo Finance UKYahoo Finance UK · Tue, 28 Jul 2026 07:00:00 GMTVERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila TimesThe Manila Times · Mon, 27 Jul 2026 11:17:21 GMT